MAPT and Alzheimer disease: In conclusion, Aβ-induced Tau-pathology is based on genetic data, biomarker data, clinical data and data from in vitro and in vivo models to be considered as a key initiating mechanism in the pathogenesis of AD, more particularly in the conversion from preclinical stages to MCI and AD [3, 4, 19, 25, 26, 31, 46, 47, 53, 54].